- Home
- PRTA vs MLYS Comparison
PRTA vs MLYS Comparison
Compare PRTA & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- MLYS
- Stock Information
- Founded
- PRTA 2012
- MLYS 2019
- Country
- PRTA Ireland
- MLYS United States
- Employees
- PRTA N/A
- MLYS N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- PRTA Health Care
- MLYS Health Care
- Exchange
- PRTA Nasdaq
- MLYS Nasdaq
- Market Cap
- PRTA 809.8M
- MLYS 893.0M
- IPO Year
- PRTA N/A
- MLYS 2023
- Fundamental
- Price
- PRTA $9.20
- MLYS $13.35
- Analyst Decision
- PRTA Buy
- MLYS Strong Buy
- Analyst Count
- PRTA 9
- MLYS 3
- Target Price
- PRTA $54.57
- MLYS $33.00
- AVG Volume (30 Days)
- PRTA 572.3K
- MLYS 1.3M
- Earning Date
- PRTA 05-07-2025
- MLYS 05-08-2025
- Dividend Yield
- PRTA N/A
- MLYS N/A
- EPS Growth
- PRTA N/A
- MLYS N/A
- EPS
- PRTA N/A
- MLYS N/A
- Revenue
- PRTA $135,157,000.00
- MLYS N/A
- Revenue This Year
- PRTA N/A
- MLYS N/A
- Revenue Next Year
- PRTA $131.71
- MLYS N/A
- P/E Ratio
- PRTA N/A
- MLYS N/A
- Revenue Growth
- PRTA 47.92
- MLYS N/A
- 52 Week Low
- PRTA $9.10
- MLYS $8.24
- 52 Week High
- PRTA $25.42
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- PRTA 26.58
- MLYS 49.65
- Support Level
- PRTA $9.30
- MLYS $10.44
- Resistance Level
- PRTA $10.45
- MLYS $14.83
- Average True Range (ATR)
- PRTA 0.81
- MLYS 1.49
- MACD
- PRTA -0.15
- MLYS -0.14
- Stochastic Oscillator
- PRTA 2.77
- MLYS 43.24
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.